Tech Company Financing Transactions

Phylogix Funding Round

On 3/10/2004, Phylogix announced $12 million in Series B financing from Atlas Venture, Radius Ventures and Canaan Partners.

Transaction Overview

Company Name
Phylogix
Announced On
3/10/2004
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series B
Investors

Atlas Venture (Lead Investor) (Jean-François Formela)

Radius Ventures (Lead Investor) (George Milne)

Canaan Partners (Seth Rudnick)

Prospect Venture Partners (David Schnell)

Proceeds Purpose
Proceeds from the round will be used in the development of Phylogix's lead preclinical candidate, FRIL, which uses a novel approach to protect the bone marrow and gastrointestinal tract from the toxicity of chemotherapy.

Company Information

Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
51 US Route One A
Scarborough, MA 04047
USA
Phone
(207) 883-8884
Website
www.phylogix.com
Email Address
Not Recorded
Overview
Phylogix is a biotechnology startup developing lectin-based therapeutic drugs focused on tissue protection and oncology.
Profile
Phylogix LinkedIn Company Profile
Social Media
Phylogix Company Twitter Account
Company News
Phylogix News
Facebook
Phylogix on Facebook
YouTube
Phylogix on YouTube

Management Team

Title
Name
Email & Social
   LinkedIn Profile   Twitter Account   News   on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/9/2004: Agitar Technologies venture capital transaction
Next: 3/10/2004: Zalicus venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.